Kornimate/medical-research-clean huggingface dataset:
task-oriented training for stroke: impact on function mobility

Conditions: Cerebrovascular Accident; Stroke

Summary: residual neurological deficits from stroke lead to gait inefficiencies, resulting in an extremely high energy cost of movement and contributing to overall disability and lower quality of life. therefore, interventions targeting movement economy should be developed for those in the chronic phase of stroke recovery. this study is designed to compare the effect of two distinctly different exercise paradigms (a higher-intensity treadmill training program and a lower-intensity group exercise program) on economy of movement during over-ground walking and activities of daily living, as well as the extent to which gains in muscular strength, muscular endurance, and balance predict changes in movement economy.


Eligibility criteria:
inclusion criteria: * stroke \> 6 months prior with residual hemiparetic gait in women or men aged 40-85 years. * completion of all regular post-stroke physical therapy * adequate language and neurocognitive function to participate in testing and training and to give adequate informed consent. * able to rise from a chair unaided. * able to walk 10 meters without human assistance. exclusion criteria: * regular structured aerobic exercise (\> 2x week). * alcohol consumption \> 3 oz. liquor, or 3 x 4 oz glasses of wine, or 3 x 12 oz. beers per day, by self-report. * clinical history of * unstable angina, * recent (\< 3 months) myocardial infarction or congestive heart failure (nyha category ii), * hemodynamically significant valvular dysfunction, * peripheral arterial obstructive disease with claudication, * major orthopedic, chronic pain, or non-stroke neuromuscular disorders restricting exercise, * pulmonary or renal failure, * poorly controlled hypertension (\>190/110), measured on at least two separate occasions * recent hospitalization for severe disease or surgery * severe or global receptive aphasia which confounds reliable testing and training. * untreated major depression as documented by a center for epidemiological studies-depression score of \>16 and confirmed by clinical interview. * pregnancy.

Keywords: exercise rehabilitation stroke
post-concussion aerobic exercise

Conditions: Concussion, Mild; Mild Traumatic Brain Injury

Summary: this study is looking at the specific role of an exercise prescription on recovery from concussion symptoms in the general population.

435 people will participate in this study. a physician will review a participant's medical history to determine if physical activity is appropriate for them. they will then be randomly assigned to 1 of 3 study groups: 1. monitoring- participants will be given a heart rate monitor to wear on their wrist for the duration of the study (until "recovered", or until 8 weeks post-concussion, whatever comes first). 2. monitoring + treadmill testing- in addition to wearing the heart rate monitor, they will undergo a treadmill test at each appointment. 3. monitoring + treadmill testing + specific exercise prescription- in addition to wearing the heart rate monitor, and treadmill test, they will receive an exercise prescription based on the results of the treadmill test. the randomization is by chance. participants have a 40/20/40% respective chance of being assigned to the study groups above. this means that out of every 5 people: 2 people will be assigned to the group 1, 1 will be assigned to the group 2, and 2 will be assigned to the group 3. both participants and the study doctor will be aware which group participants are in. regardless of the group assigned, participants will receive an exercise prescription form at each appointment, as per usual care. the prescription will be based on the physician's judgement. if a participant is in group 3, their prescription will also take into account the results of the treadmill test. recovery will be determined using a 3-step approach: 1. self-reported symptoms, 2. clinic physician's opinion, 3. treadmill test results (if applicable).

Eligibility criteria:
inclusion criteria: * patients that provide written informed consent prior to entry into the study * patients referred from the emergency department (ed) with recent (\<1 week) diagnosis of concussion by ed physician * gcs score of 13-15 on presentation to the ed * scat score \> 9 at week 1 * physician cleared for exercise; low risk for cardiac disease (defined as no cardiopulmonary symptoms and meet no more than one risk factor for heart disease) * willing to exercise exclusion criteria: * evidence of intracranial hemorrhage, contusion or injury on brain imaging (ct scan) * beta-blocker medication * high dose (\>50mg/day) tricyclic antidepressant medication * pre-existing or current orthopedic injuries preventing exercise * pre-existing vestibular disease preventing exercise * heartrate increase \<30 bpm from rest on treadmill test * deemed asymptomatic from concussion by clinic physician * unable/unwilling to follow commands

Keywords: concussion mild traumatic brain injury aerobic exercise
measurement of bladder pressure with a novel external device (cystomanometer) - home use

Conditions: Urinary Bladder, Neurogenic

Summary: the investigators have developed a novel pressure monitoring device that hooks to standard urinary catheters that are used by patients with a neurogenic bladder on daily clean intermittent catheterization. the device has already been demonstrated to be accurate compared to the gold standard in clinic urodynamics. this study will assess the patients and care givers ability and experience using the device in a home setting.

for patients with neurogenic bladder, regular monitoring of bladder pressure and capacity is a critical component of maintaining renal and urinary health. this monitoring is currently done by in-office urodynamics testing (uds). this testing is done intermittently, leaving open the possibility of worsening of bladder function and renal deterioration between testing sessions. this study utilizes a novel pressure monitoring device which is portable and attaches to the end of a standard urinary catheter. the investigators will be investigating if this device can be used by patients or their caregivers in a home setting. this study will enroll patients with neurogenic bladder that currently perform clean intermittent catheterization on a daily basis as part of their regular care. the patients will be asked to use the device at least twice a day for two weeks.

Eligibility criteria:
inclusion criteria: * must have diagnosed neurogenic bladder exclusion criteria: * none

Keywords: urodynamics neurogenic bladder
linear source registry for prostate cancer

Conditions: Prostate Cancer

Summary: ongoing follow up for subjects implanted with the linear source string for prostate cancer.

this registry is being conducted to provide long term analysis on the use of the linear civastring source for prostate cancer. prospective data collection will record and demonstrate biochemical response rates. long term side effects and adverse events will be monitored.

Eligibility criteria:
inclusion criteria: * age \> 18 years old * plans to remain in care of enrolling physician for 5 years * \> 5 years life expectancy * signed informed consent * enrolled within 6 weeks of implant or within 365 days of prior implant exclusion criteria: * not willing or able to comply with protocol visit schedule
assessment of the effectiveness of virtual reality as a learning tool for relaxation techniques in reducing pediatric migraines and tension type headache

Conditions: Chronic Headache; Migraine; Tension Type Headache

Summary: the goal of this interventional study is to assess the efficacy of a therapeutic intervention aimed at diminishing pediatric chronic headache. this intervention is based on the development of relaxation skills, particularly the practice of deep breathing, using virtual reality in conjunction with a biofeedback device. specifically, it aims to assess the relevance of this tool both in learning relaxation techniques and in changing cognitions involved in pain adjustment, such as self-efficacy and pain catastrophizing. the main hypothesis is that the intervention using virtual reality will lead to greater daily use of the relaxation techniques learned, as well as an increase in the associated self-efficacy, resulting in a reduction in headaches (in terms of frequency and intensity) both immediately after the intervention and two months later. a secondary hypothesis is that this intervention will contribute to a decrease in negative pain perceptions, pain catastrophizing, and functional disability. a tertiary hypothesis is that the intervention will lead to an improvement in the child's quality of life. the effects of this intervention will be compared to those of a similar intervention without the use of virtual reality, as well as to a control condition in which only psychoeducation is provided.


Eligibility criteria:
inclusion criteria: * having a history of headaches for at least 6 months, or having been diagnosed with migraines and/or chronic tension-type headaches according to the criteria of the international headache society (ihs) by a pediatric neurologist. exclusion criteria: * having an epilepsy disorder

Keywords: virtual reality
theophylline as a treatment for children with pseudohypoparathyroidism type 1a (albright hereditary osteodystrophy)

Conditions: Pseudohypoparathyroidism Type 1a; Albright Hereditary Osteodystrophy

Summary: this study will test an investigational drug, theophylline, in children with pseudohypoparathyroidism type 1a (php1a). this study involves a 3 day visit to the vanderbilt clinical research center.

study measures will be done at baseline and during a 24h infusion of iv theophylline. theophylline levels will be drawn to ensure therapeutic dosing and to monitor for toxicity. measures include laboratory values, response to pth infusion and resting energy expenditure.

Eligibility criteria:
inclusion criteria: 1. age 10 to 21 years old 2. english proficiency 3. clinical and genetic diagnosis of php1a exclusion criteria: 1. use of a pde inhibitor in the past 30 days 2. history of a seizure disorder unrelated to hypocalcemia 3. history of a cardiac arrhythmia (not including bradycardia) 4. history of hepatic insufficiency 5. ast or alt \>2x upper limit of normal 6. total bilirubin \>1.5 x upper limit of normal (unless patient has a diagnosis of gilbert's syndrome and no other causes leading to hyperbilirubinemia are identified) 7. congestive heart failure 8. cigarette use in the past 30 days 9. alcohol use within the past 24 hours 10. current pregnancy 11. untreated hypothyroidism (defined as free t4 level \ 10 mcu/ml) 12. active peptic ulcer disease 13. fever \>101 degrees in the past 24 hours 14. current use of medications known to effect theophylline levels (listed below) 15. severe sleep apnea requiring bipap drugs with clinically significant drug interactions with theophylline: * allopurinol * cimetidine * ciprofloxacin * clarithromycin * enoxacin * ephedrine * erythromycin * estrogen * flurazepam * fluvoxamine * lithium * lorazepam * methotrexate * midazolam * pentoxifylline * propranolol * rifampin * sulfinpyrazone * tacrine * thiabendazole * ticlopidine * troleandomycin * verapamil
liquid biopsy evaluation and repository development at princess margaret

Conditions: Cancer; Breast Cancer; Lung Cancer; Colon Cancer; Ovarian Cancer; Melanoma; Lymphoma; Leukemia; Mutation; Lynch Syndrome; Cowden Syndrome; BRCA1 Mutation; BRCA2 Mutation; Uterine Cancer; Myeloma; Kidney Cancer; Head and Neck Cancer; Meningioma

Summary: the objective of this protocol is to develop an institution-wide liquid biopsy protocol that will establish a common process for collecting blood and corresponding archived tumor specimens for future research studies at the university health network's princess margaret cancer centre. circulating cell-free nucleic acids (cfna), including cell-free dna (cfdna) and cell-free rna (cfrna), are non-invasive, real-time biomarkers that can provide diagnostic and prognostic information before cancer diagnosis, during cancer treatment, and at disease progression. cancer research scientists and clinicians at the princess margaret are interested in incorporating the collection of peripheral blood samples ("liquid biopsies") into research protocols as a means of non-invasively assessing tumor progression and response to treatment at multiple time points during a patient's course of disease.


Eligibility criteria:
inclusion criteria: 1. patients with either histological confirmation of a solid tumor or hematological malignancy, or patients identified as high-risk for cancer (based on identified aberration in cancer predisposition gene or on hormonal and/or family history without known aberration). 2. patient must be ≥ 18 years old. 3. all patients must have signed and dated an informed consent form for this liberate study. 4. if patients are being co-consented for a separate primary research study listed in appendix i, they must fulfill the eligibility criteria for that separate primary research study. if there is a discrepancy in the eligibility criteria between protocols, the separate primary research study's criteria take precedence. exclusion criteria: none

Keywords: high risk liquid biopsy circulating tumor dna blood molecular profiling next generation sequencing solid tumors hematological
biomarkers to distinguish benign from malignant thyroid neoplasm

Conditions: Cancer of the Thyroid; Neoplasms, Thyroid; Thyroid Adenoma; Thyroid Cancer; Thyroid Carcinoma

Summary: this protocol will evaluate microrna biomarkers in blood and fine-needle aspirate biopsies (fnab) of thyroid nodules. microrna profiles will be determined and evaluated for their utility in pre-operative diagnosis, in particular to distinguish benign from malignant throid neoplasms. post-surgical fresh-frozen thyroid cancer tissue will be assessed for somatic mutations, mrna, and microrna expression patterns. ffpe tissue will be used to obtain h\&e and unstained slides to specific biomarker results using immunohistochemistry.

this protocol requires the collection of blood (5 ml), fine-needle aspirate biopsies (fnab), and post-surgical thyroid cancer tissue. the post surgical tissue includes fresh-frozen tissue that is considered waste and in excess of that required for pathologic diagnosis, and archived formalin-fixed, paraffin-embedded tissue (ffpe). the blood will be used as a substrate for assessing known markers, including microrna expression patterns that may be useful to predict disease and thyroid cancer morphotype. the fnabs will be used to screen the potential of markers for pre-operative diagnosis. the post-surgical fresh-frozen thyroid cancer tissue will be used to isolate dna and rna in order to assess somatic mutations (ras and pax8/ppar-gamma rearrangement) and messenger rna, and microrna expression patterns. the ffpe tissue will be used to obtain h\&e and unstained slides to validate results using immunohistochemistry. the goal of these studies is to define molecular markers that will accurately distinguish benign from malignant disease and the multiple thyroid cancer phenotypes. current methods of distinguishing benign from malignant disease requires a detailed post-surgical analysis and no known markers have yet been identified to reliably differentiate the multiple thyroid cancer morphotypes.

Eligibility criteria:
inclusion criteria: * patient with palpable thyroid nodule suspicious for thyroid neoplasm * patient selected to undergo fine needle biopsy for cytologic diagnosis * male (18 years of age or older) * female (18 years of age or older)

Keywords: thyroid cancer thyroid neoplasm thyroid adenoma
nonmyeloablative allo sct for the treatment of hematologic disorders

Conditions: AML; ALL; CML Chronic Phase, Accelerated Phase, or Blast Crisis; CLL; MDS; RELAPSED NON-HODGKIN'S OR HODGKIN'S LYMPHOMA; APLASTIC ANEMIA; MULTIPLE MYELOMA; MYELOPROLIFERATIVE DISORDER (P Vera, CMML, ET)

Summary: the purpose of this study is to provide allogeneic stem cell transplantation to patients who have not traditionally undergone this procedure because of it high incidence of treatment related side effects. we hope to decrease these side effects by decreasing the chemotherapy dose prior to transplant (non-myeloablative, smaller dose of chemotherapy given so bone marrow is not completely eliminated) and by using donated stem cells to treat cancer of the blood.


Eligibility criteria:
inclusion criteria - patient: * aml, all,cml chronic phase, accelerated phase, or blast crisis, cll, mds, relapsed non-hodgkin's or hodgkin's lymphoma, aplastic anemia, multiple myeloma, myeloproliferative disorder (p vera, cmml, et * age less than 65 years * patients must have a healthy family member who is hla-identical to the recipient or has 1 antigen mismatch and who is willing to receive a course of g-csf and undergo 2-4 daily leukaphereses * each patient must sign an informed consent and be willing to participate as a research subject after having been advised of the nature and risk of the study prior to entering protocol inclusion criteria - donor: * absence of hematologic or marrow function related diseases that interferes with the collection of sufficient numbers of normal progenitor cells * absence of any medical condition that would pose a serious health risk by undergoing peripheral blood stem cell harvest * negative hiv, htlv-1, hepatitis b surface antigen and hepatitis c * the donor must be blood relation. a prospective related donor must be at least genotypically hla-a, b, dr identical to the patient, but can differ for 1 hla-locus. exclusion criteria - patient: * active cns involvement * females who are pregnant or breast feeding * ecog performance status \> 1. karnofsky performance status \< 80% * lvef \< 40% * active viral, bacterial, or fungal infection * patients seropositive for hiv; htlv -1 * patients not providing informed consent * patients with known hypersensitivity to e. coli derived product exclusion criteria - donor: * a positive hiv infection or htlv - 1 test or evidence of active/persistent viral hepatitis infection. presence of any medical condition that would pose a serious health risk by undergoing peripheral blood stem cell harvest. donors with known hypersensitivity to e. coli derived products.

Keywords: aml all cml cll mds nhl hodgkin's lymphoma aplastic anemia multiple myeloma myeloproliferative disorder allogeneic stem cell transplant hematologic disorders cyclophosphamide fludarabine cyclosporine methotrexate g-csf gvhd engraftment chimerism
the effect of tendon tears on lateral epicondylitis

Conditions: Lateral Epicondylitis; Tennis Elbow; Tendon Tear

Summary: common extensor tendon (cet) tears that can be detected with ultrasonography (us) may be associated with worsening clinical and other ultrasonographic parameters in patients with le. in this retrospective evaluation of patients with lateral epicondylitis (le), the effect of common extensor tendon (cet) tears revealed by ultrasonography (us) with demographic, clinical, and other us findings was investigated.

the files of 227 patients with le who applied to dokuz eylül university faculty of medicine, department of physical medicine and rehabilitation clinic and met the inclusion and exclusion criteria were reviewed retrospectively. the demographic characteristics of the patients were recorded. first of all, common extensor tendon tears, if it existed, were demonstrated with ultrasonography. then, primary and secondary outcome measures were performed. maximum tendon thickness measurements (capitellar - radiocapitellar) and the presence of bone abnormality were detected with ultrasonography of the lateral epicondyle region of the humerus. the vas was used to assess pain and was evaluated separately for pain at rest (vas-rest), at night (vas-night), and during adl (vas-adl). force was applied on the lateral epicondyle using a standard pressure algometer (baseline®) to evaluate the patient's sensitivity to pain. the pressure at which the patient first felt pain and the average value in kg/cm2 (repeated three times) were recorded. prtee consists of two sub-sections (pain and function): the severity of pain in the elbow and functional deficiencies. the turkish version of the prtee questionnaire was used the hand dynamometer (jamar®) was used to assess the hand grip strength. the patient was positioned with sitting, shoulder adduction, elbow 90° flexion, and forearm in a position between supination and pronation. the average value in kilogram-force (repeated three times). between repeated measures 1-minute resting, periods were given.

Eligibility criteria:
inclusion criteria: * age between 18-65 years * diagnosis of le based on clinical parameters and us findings * duration of symptoms ranging from 2 to 12 weeks * agreement to participate in the study exclusion criteria: * le findings in the other extremity * has received any treatment for lateral epicondylitis before * previous elbow surgery * history of elbow fracture * upper extremity muscle weakness due to radiculopathy or neuropathy * the presence of concurrent neurological, rheumatic, psychiatric, or malignant conditions * pregnancy * inability to comply with the study requirements

Keywords: lateral epicondylitis tennis elbow extensor tendon tendon tear ultrasonography
pan-promise to detect post-ercp pancreatitis symptoms

Conditions: Post-ERCP Acute Pancreatitis

Summary: the aim of this study is to use a validated patient-reported outcome measure to evaluate how many patients have symptoms of pancreatitis after ercp and how it correlates with their quality of life and productivity.

this project will measure the impact of a recently validated patient-reported outcome measure for acute pancreatitis, pan-promise, to detect post-ercp pancreatitis symptoms and capture its morbidity. the study will compare the change of pan-promise before and after ercp to the current standard diagnostic criteria for post-ercp pancreatitis, the cotton consensus criteria. the main limitations of the cotton-consensus criteria are that it fails to capture outpatient or ambulatory morbidity, uses length of stay to define the severity of pancreatitis without accounting for local or systemic complications for pancreatitis, and it has limited sensitivity in patients with chronic symptoms such as patients with chronic pancreatitis or pancreatic adenocarcinoma. these limitations have impeded the evaluation of potential therapies to prevent post-ercp pancreatitis. pan-promise will help capture and quantitate the morbidity related to post-ercp pancreatitis and thus will enhance our ability to optimize outcomes following ercp.

Eligibility criteria:
inclusion criteria: 1. patients undergoing ercp 2. age \>= 18 years old 3. intact major papilla exclusion criteria: 1. unwillingness or inability to consent for the study 2. age \< 18 years 3. standard contraindications to ercp 4. intrauterine pregnancy 5. prior hepaticojejunostomy in a patient undergoing ercp for a bile duct indication 6. prior pancreaticojejunostomy in a patient undergoing ercp for a pancreatic duct indication 7. low probability of completing the follow-up 8. acute pancreatitis (by the revised atlanta criteria) in the seven days prior to ercp. 9. patients who do not answer at least 80% of the questions on the baseline and 48-hour follow-up survey. 10. patients who could not be contacted via a telephone call to assess for post-ercp complications at 48-72 hours. 11. patients who speak a language other than english, spanish, bulgarian, mandarin, english, french, german, greek, hungarian, italian, korean, polish, portuguese, romanian, russian, turkish, ukrainian, or hindi (as the pan-promise has only been translated and validated in these languages.